Per Hviid Gundtoft1,2,3, Alma Becic Pedersen4, Claus Varnum5, Søren Overgaard6,7. 1. Department of Orthopaedics Surgery, Kolding Hospital, Kolding, Denmark. per.hviid.gundtoft@rsyd.dk. 2. Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark. per.hviid.gundtoft@rsyd.dk. 3. Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. per.hviid.gundtoft@rsyd.dk. 4. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 5. Department of Orthopaedic Surgery, Vejle Hospital, Vejle, Denmark. 6. Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark. 7. Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
Abstract
BACKGROUND: Revision for prosthetic joint infection (PJI) has a major effect on patients' health but it remains unclear if early PJI after primary THA is associated with a high mortality. QUESTIONS/PURPOSES: (1) Do patients with a revision for PJI within 1 year of primary THA have increased mortality compared with patients who do not undergo revision for any reason within 1 year of primary THA? (2) Do patients who undergo a revision for PJI within 1 year of primary THA have an increased mortality risk compared with patients who undergo an aseptic revision? (3) Are there particular bacteria among patients with PJI that are associated with an increased risk of death? METHODS: This population-based cohort study was based on the longitudinally maintained Danish Hip Arthroplasty Register on primary THA performed in Denmark from 2005 to 2014. Data from the Danish Hip Arthroplasty Register were linked to microbiology databases, the National Register of Patients, and the Civil Registration System to obtain data on microbiology, comorbidity, and vital status on all patients. Because reporting to the register is compulsory for all public and private hospitals in Denmark, the completeness of registration is 98% for primary THA and 92% for revisions (2016 annual report). The mortality risk for the patients who underwent revision for PJI within 1 year from implantation of primary THA was compared with (1) the mortality risk for patients who did not undergo revision for any reason within 1 year of primary THA; and (2) the mortality risk for patients who underwent an aseptic revision. A total of 68,504 primary THAs in 59,954 patients were identified, of those 445 primary THAs underwent revision for PJI, 1350 primary THAs underwent revision for other causes and the remaining 66,709 primary THAs did not undergo revision. Patients were followed from implantation of primary THA until death or 1 year of followup, or, in case of a revision, 1 year from the date of revision. RESULTS: Within 1 year of primary THA, 8% (95% CI, 6%-11%) of patients who underwent revision for PJI died. The adjusted relative mortality risk for patients with revision for PJI was 2.18 (95% CI, 1.54-3.08) compared with the patients who did not undergo revision for any cause (p < 0.001). The adjusted relative mortality risk for patients with revisions for PJI compared with patients with aseptic revision was 1.87 (95% CI, 1.11-3.15; p = 0.019). Patients with enterococci-infected THA had a 3.10 (95% CI, 1.66-5.81) higher mortality risk than patients infected with other bacteria (p < 0.001). CONCLUSIONS: Revision for PJI within 1 year after primary THA induces an increased mortality risk during the first year after the revision surgery. This study should incentivize further studies on prevention of PJI and on risk to patients with the perspective to reduce mortality in patients who have had THA in general and for patients with PJI specifically. LEVEL OF EVIDENCE: Level III, therapeutic study.
BACKGROUND: Revision for prosthetic joint infection (PJI) has a major effect on patients' health but it remains unclear if early PJI after primary THA is associated with a high mortality. QUESTIONS/PURPOSES: (1) Do patients with a revision for PJI within 1 year of primary THA have increased mortality compared with patients who do not undergo revision for any reason within 1 year of primary THA? (2) Do patients who undergo a revision for PJI within 1 year of primary THA have an increased mortality risk compared with patients who undergo an aseptic revision? (3) Are there particular bacteria among patients with PJI that are associated with an increased risk of death? METHODS: This population-based cohort study was based on the longitudinally maintained Danish Hip Arthroplasty Register on primary THA performed in Denmark from 2005 to 2014. Data from the Danish Hip Arthroplasty Register were linked to microbiology databases, the National Register of Patients, and the Civil Registration System to obtain data on microbiology, comorbidity, and vital status on all patients. Because reporting to the register is compulsory for all public and private hospitals in Denmark, the completeness of registration is 98% for primary THA and 92% for revisions (2016 annual report). The mortality risk for the patients who underwent revision for PJI within 1 year from implantation of primary THA was compared with (1) the mortality risk for patients who did not undergo revision for any reason within 1 year of primary THA; and (2) the mortality risk for patients who underwent an aseptic revision. A total of 68,504 primary THAs in 59,954 patients were identified, of those 445 primary THAs underwent revision for PJI, 1350 primary THAs underwent revision for other causes and the remaining 66,709 primary THAs did not undergo revision. Patients were followed from implantation of primary THA until death or 1 year of followup, or, in case of a revision, 1 year from the date of revision. RESULTS: Within 1 year of primary THA, 8% (95% CI, 6%-11%) of patients who underwent revision for PJI died. The adjusted relative mortality risk for patients with revision for PJI was 2.18 (95% CI, 1.54-3.08) compared with the patients who did not undergo revision for any cause (p < 0.001). The adjusted relative mortality risk for patients with revisions for PJI compared with patients with aseptic revision was 1.87 (95% CI, 1.11-3.15; p = 0.019). Patients with enterococci-infectedTHA had a 3.10 (95% CI, 1.66-5.81) higher mortality risk than patients infected with other bacteria (p < 0.001). CONCLUSIONS: Revision for PJI within 1 year after primary THA induces an increased mortality risk during the first year after the revision surgery. This study should incentivize further studies on prevention of PJI and on risk to patients with the perspective to reduce mortality in patients who have had THA in general and for patients with PJI specifically. LEVEL OF EVIDENCE: Level III, therapeutic study.
Entities:
Keywords:
Charlson Comorbidity Index Score; High Mortality Risk; Increase Mortality Risk; Mortality Risk; Prosthetic Joint Infection
Authors: Mohammad R Rasouli; Mohan S Tripathi; Robert Kenyon; Nathan Wetters; Craig J Della Valle; Javad Parvizi Journal: Clin Orthop Relat Res Date: 2012-10 Impact factor: 4.176
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Steven M Kurtz; Edmund Lau; Jordana Schmier; Kevin L Ong; Ke Zhao; Javad Parvizi Journal: J Arthroplasty Date: 2008-04-10 Impact factor: 4.757
Authors: Sandra K Thygesen; Christian F Christiansen; Steffen Christensen; Timothy L Lash; Henrik T Sørensen Journal: BMC Med Res Methodol Date: 2011-05-28 Impact factor: 4.615
Authors: Qun Yan; Melissa J Karau; Kerryl E Greenwood-Quaintance; Jayawant N Mandrekar; Douglas R Osmon; Matthew P Abdel; Robin Patel Journal: J Clin Microbiol Date: 2018-05-25 Impact factor: 5.948
Authors: Charlotte Bielefeld; Harald Engler; Marcus JÄger; Alexander Wegner; Dennis Wassenaar; Andre Busch Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Jie J Yao; Hilal Maradit Kremers; Matthew P Abdel; Dirk R Larson; Jeanine E Ransom; Daniel J Berry; David G Lewallen Journal: Clin Orthop Relat Res Date: 2018-02 Impact factor: 4.176
Authors: Ashley E Levack; Erika L Cyphert; Mathias P Bostrom; Christopher J Hernandez; Horst A von Recum; Alberto V Carli Journal: Curr Rheumatol Rep Date: 2018-04-30 Impact factor: 4.592
Authors: M M Ploeger; C Jacobs; M Gathen; E Kaup; T M Randau; M J Friedrich; G T Hischebeth; M D Wimmer Journal: Arch Orthop Trauma Surg Date: 2018-06-11 Impact factor: 3.067